Protocol Page


	Study ID (Protocol Number)
	CV181-168


	STUDY LOCATIONS*
	Barat Research Group, Inc. Charlotte, NC 28262 Recruiting	Clinical Research Advantage Fremont, NE 68025 Recruiting
	Cassidy Medical Group/Clinical Research Advantage Tempe, AZ 85282 Recruiting	Clinical Research Advantage, Inc Phoenix, AZ 85020 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
	STUDY OVERVIEW
	The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.